Cardizem LA

See also: Generic Cardizem, Generic Cardizem CD

Cardizem LA is a brand name of diltiazem, approved by the FDA in the following formulation(s):

CARDIZEM LA (diltiazem hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: VALEANT INTL
  
  Approval date: February 6, 2003
  
  Strength(s): 120MG ^[AB], 180MG ^[AB], 240MG ^[AB], 300MG ^[AB], 360MG ^[AB], 420MG ^[RLD][AB]

Has a generic version of Cardizem LA been approved?

A generic version of Cardizem LA has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Cardizem LA and have been approved by the FDA:

diltiazem hydrochloride tablet, extended release; oral

• 
  Manufacturer: WATSON LABS FLORIDA
  
  Approval date: March 15, 2010
  
  Strength(s): 120MG ^[AB], 180MG ^[AB], 240MG ^[AB], 300MG ^[AB], 360MG ^[AB], 420MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cardizem LA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Extended release form of diltiazem
  Patent 5,529,791
  Issued: June 25, 1996
  Inventor(s): Deboeck; Arthur M. & Baudier; Philippe R.
  Assignee(s): Galephar P.R., Inc., Ltd.
  An extended-release galenical form of Diltiazem or a pharmaceutically acceptable salt thereof, which comprises beads containing said Diltiazem or a pharmaceutically acceptable salt thereof as an active ingredient and a wetting agent, said beads being coated with a microporous membrane comprising at least a water-soluble or water-dispersible polymer or copolymer and a pharmaceutically acceptable adjuvant.
  
  Patent expiration dates:
  
  
  • June 25, 2013
    
  
  



• 
  Cushioning wax beads for making solid shaped articles
  Patent 6,923,984
  Issued: August 2, 2005
  Inventor(s): Remon; Jean Paul
  Assignee(s): Universiteit Gent
  Biologically inactive cushioning beads comprise at least one compressible cushioning component consisting essentially of a microcrystalline hydrocarbon wax or a natural wax, the said wax being at least 30% by weight of the biologically inactive cushioning beads. Such beads are useful for making solid shaped articles containing biologically active ingredients by compression.
  
  Patent expiration dates:
  
  
  • February 25, 2021
    
    ✓ 
    Drug product
  
  



• 
  Chronotherapeutic diltiazem formulations and the administration thereof
  Patent 7,108,866
  Issued: September 19, 2006
  Inventor(s): Albert; Kenneth Stephen & Maes; Paul José
  Assignee(s): Biovall Laboratories International SRL
  A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 15 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.
  
  Patent expiration dates:
  
  
  • December 17, 2019
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
    ✓ 
    Drug product
  
  

See also...

• Cardizem LA 24-Hour Extended-Release Beads Tablets Consumer Information (Wolters Kluwer)
• Cardizem LA Consumer Information (Cerner Multum)
• Cardizem LA Advanced Consumer Information (Micromedex)
• Diltiazem Consumer Information (Drugs.com)
• Diltiazem Consumer Information (Wolters Kluwer)
• Diltiazem 12-Hour Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Diltiazem 24-Hour Extended-Release Beads Capsules Consumer Information (Wolters Kluwer)
• Diltiazem 24-Hour Extended-Release Beads Tablets Consumer Information (Wolters Kluwer)
• Diltiazem 24-Hour Sustained-Release Beads Capsules Consumer Information (Wolters Kluwer)
• Diltiazem 24-Hour Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Diltiazem Immediate-Release Tablets Consumer Information (Wolters Kluwer)
• Dilt-CD Consumer Information (Cerner Multum)
• Diltiazem Consumer Information (Cerner Multum)
• Dilt-CD Advanced Consumer Information (Micromedex)
• Diltiazem Advanced Consumer Information (Micromedex)
• Diltiazem Intravenous Advanced Consumer Information (Micromedex)
• Diltiazem Hydrochloride AHFS DI Monographs (ASHP)